American Society of Gene + Cell Therapy



田

PRE-MEETING Workshop

VIRAL VECTOR DEVELOPMENT WORKSHOP MAY 15, 2022

0

Q

H



TRANSFORMING THE GENE THERAPY LANDSCAPE WITH AI-POWERED AAV VECTORS

Dyno Therapeutics is pioneering machineguided design with the **CapsidMap™** platform: leveraging cutting-edge technologies to experimentally characterize millions of AAV capsids *in vivo*, then applying **artificial intelligence** and **machine learning** to design highly effective and targeted **AAV vectors** that expand therapeutic possibilities for millions of patients.



PARTNER WITH US

Partners can license CapsidMap vectors designed to match their unique delivery needs across a wide range of disease areas and indications. Contact us at **bd@dynotx.com** and learn more about our current partnerships at **dynotx.com/partners**.



JOIN OUR TEAM

We are recruiting for dynamic and driven AAViators! Our culture empowers diverse teams of high-potential problem solvers to transform patient lives with cutting-edge science. See all open positions at **dynotx.com/careers**.

ATTEND OUR SYMPOSIUM



Wednesday, May 18th 12-1:30pm EST Room 202

www.dynotx.com

343 Arsenal St, Suite 101, Watertown, MA 02472 © 2022 Dyno Therapeutics. All rights reserved.

PackGene ACCELERATE GENETHERAPY

PackGene is a leading CRO and CDMO company providing integrated, AAV-based gene therapy solutions to institutions and biotech companies.







GMP AAV Production



Quality Assurance & Regulatory

Innovation · Collaboration · Elevation

Find out more at packgene.com

Process & Analytical

Development







VIRAL VECTOR DEVELOPMENT

SUNDAY, MAY 15, 2022

All times listed below ET

Planned by the Viral Gene Transfer Vectors Committee Co-chairs: Carol Miao, PhD Anna Maurer, PhD

Description

This workshop will provide guidance on how to choose, design, and produce the appropriate viral vector for your purposes. Comprehensive reviews of lentiviral, adenoviral, and other vectors will discuss considerations of viral tropism, vector production in small-scale for laboratories, animal model choices, and vector dose. A final session will be dedicated to developing adenoassociated viral vectors for preclinical and clinical applications, including capsid choice, expression cassette design, and vector production from small to large scales.





VIRAL VECTOR DEVELOPMENT

Schedule

All times listed below ET

8:00-8:20 AM

Overview of Viral Vector Platforms Negin Martin, PhD, National Institute of Environmental Health Sciences

8:20-8:40 AM

Lentiviral Vector Design and Applications Axel Schambach, PhD, Hannover Medical School

8:40-9:00 AM

Adenoviral Vector Design and Applications for Immune Mediated Gene Therapy: From the Bench to Clinical Implementation Maria G. Castro, PhD, University of Michigan Medical School

9:00-9:20 AM

From the Lab to the Clinic: Designing Preclinical Programs to Assess Efficacy and Safety for Novel Viral Vectors Eva Andres-Mateos, PhD, Atsena Therapeutics, Inc.

9:20-9:40 AM

Panel Discussion

9:40–10:00 AM Break



VIRAL VECTOR DEVELOPMENT

10:00-10:20 AM

AAV Vector Development Mark Kay, PhD, Stanford University

10:20-10:40 AM

AAV Capsid Engineering and Library Approaches Ben Deverman, PhD, Broad Institute

10:40-11:00 AM

AAV Vector Production from Small to Large Scales Nathalie Clement, PhD, Unicorn Consultations, LLC

11:00-11:20 AM

AAV Vectors : Transgene Design Charles Venditti, MD, PhD, National Human Genome Research Institute

11:20-11:40 AM

AAV Genomics and Its Implication in Gene Therapy Weidong Xiao, PhD, Indiana University

11:40 AM-12:00 PM Panel Discussion

25th Annual Meeting







PackGene

25th Annual Meeting